Meeting
2016 Palliative and Supportive Care in Oncology Symposium
Practice patterns and outcomes of rivaroxaban usage in patients with cancer.
Authors
Carmelita P. Escalante
The University of Texas MD Anderson Cancer Center, Houston, TX
Carmelita P. Escalante, Ali Zalpour, Juhee Song, Marsha N. Richardson, Tony Lam, Josiah Halm, SWamique Yusuf, Shuwei Gao
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session B
Track
Biologic Basis of Symptoms and Treatment Toxicities,Psycho-oncology,End-of-Life Care,Survivorship,Management/Prevention of Symptoms and Treatment Toxicities,Psychosocial and Spiritual Care,Communication in Advanced Cancer
Sub Track
Symptom management
Citation
J Clin Oncol 34, 2016 (suppl 26S; abstr 194)
DOI
10.1200/jco.2016.34.26_suppl.194
Abstract #
194
Poster Bd #
F8
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
Real-world utilization and comparative effectiveness of treatment options in cancer-associated thrombosis: A propensity score weighed analysis.
First Author: Irbaz Bin Riaz
Poster
2021 ASCO Quality Care Symposium
Evaluation of direct oral anticoagulant use for cancer-associated venous thromboembolism (VTE) in lung cancer.
First Author: Leila Rostamnjad
Poster
2021 ASCO Annual Meeting
The comparative effectiveness of direct oral anti-coagulants and low molecular weight heparins for prevention of recurrent venous thromboembolism in cancer: The CANVAS pragmatic randomized trial.
First Author: Deborah Schrag
Poster
2021 Genitourinary Cancers Symposium
A retrospective real-world major bleeding (MB) comparison of direct oral anticoagulants (DOAC) and low molecular weight heparin (LMWH) in genitourinary cancer-associated venous thromboembolism (GU-CAVTE) with reported randomized clinical trials (RTC).
First Author: Ulyana Dashkevych